# Xiubao Ren

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/xiubao-ren/

## Facts

| Field | Value |
| --- | --- |
| Citations | 15,130 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 62 |
| i10-index | 195 |
| Last Known Institution | National Medical Products Administration |
| OpenAlex ID | https://openalex.org/A5100606004 |
| ORCID iD | 0000-0003-4137-2049 |
| Works | 449 |

## Researcher papers

- [Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis](https://scholariq.org/papers/breast-cancer-secreted-mir-122-reprograms-glucose-metabolism-in-premetastatic/)
- [Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis](https://scholariq.org/papers/abrogation-of-tgf-signaling-in-mammary-carcinomas-recruits-gr-1-cd11b-myeloid/)
- [Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer](https://scholariq.org/papers/myeloid-derived-suppressor-cells-suppress-antitumor-immune-responses-through-ido/)
- [Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-pemetrexed-versus-chemotherapy-alone-in/)
- [Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells](https://scholariq.org/papers/cancer-cell-secreted-exosomal-mir-105-promotes-tumour-growth-through-the-myc/)
- [Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-first-line-serplulimab-vs-placebo-added-to-chemotherapy-on-survival-in/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma](https://scholariq.org/papers/hdac-inhibitors-enhance-t-cell-chemokine-expression-and-augment-response-to-pd-1/)
- [Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB](https://scholariq.org/papers/macrophage-immunomodulation-by-breast-cancer-derived-exosomes-requires-toll-like/)
- [Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM](https://scholariq.org/papers/transforming-growth-factor-regulates-the-sphere-initiating-stem-cell-like/)
- [20P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure: An interim analysis of GPS study](https://scholariq.org/papers/20p-genomic-profiles-in-egfr-mutant-locally-advanced-or-metastatic-nsclc/)
- [685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China](https://scholariq.org/papers/685p-genomic-profiles-in-egfr-mutant-locally-advanced-or-metastatic-nsclc/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [National Medical Products Administration](https://scholariq.org/institutions/national-medical-products-administration/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.